Roche's Spark in Gene-Therapy Collaboration With Senti Bio
April 13 2021 - 10:10AM
Dow Jones News
By Colin Kellaher
Roche Holding AG's Spark Therapeutics unit on Tuesday said it
signed a collaboration and option agreement with Senti Biosciences
that could be worth more than $645 million to the privately held
gene-circuit company.
Spark said the collaboration will combine its investigational
gene therapies targeting the central nervous system, eye and liver
with Senti's gene-circuit technology.
Spark said Senti will be responsible for designing, building and
testing synthetic promoters for use in developing certain gene
therapies, while Spark will have the option to license promoters
and will be responsible for conducting preclinical, clinical and
commercialization activities for any gene therapy candidates using
the promoters.
Spark, which Roche acquired in 2019 for $4.8 billion, said the
aggregate potential value of upfront, opt-in and milestone payments
to South San Francisco, Calif.-based Senti could top $645
million.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
April 13, 2021 09:55 ET (13:55 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.
Roche (QX) (USOTC:RHHBY)
Historical Stock Chart
From Aug 2024 to Sep 2024
Roche (QX) (USOTC:RHHBY)
Historical Stock Chart
From Sep 2023 to Sep 2024